P. Turner

发表

P. Turner, 2005 .

The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.

R. Masterton, D. Nicolau, P. Turner, 2005, The Journal of antimicrobial chemotherapy.

Rapid community point-of-care testing for COVID-19 (RAPTOR-C19): protocol for a platform diagnostic study

S. de Lusignan, R. Perera, R. Byford, 2021, Diagnostic and Prognostic Research.

In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii.

S. Sinto, P. Turner, C. Mendes, 2005, Diagnostic microbiology and infectious disease.

Impact of point-of-care C reactive protein in ambulatory care: a systematic review and meta-analysis

A. Van den Bruel, J. Verbakel, P. S. Tan, 2019, BMJ Open.

Pseudomonas aeruginosa clonal dissemination in Brazilian intensive care units.

S. Sinto, P. Turner, C. Oplustil, 2005, Enfermedades infecciosas y microbiologia clinica.

Klebsiella pneumoniae with multiple antimicrobial resistance.

P. Turner, C. Mendes, C. Kiffer, 2004, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

In-vitro diagnostic point-of-care tests in paediatric ambulatory care: A systematic review and meta-analysis

A. Van den Bruel, O. van Hecke, J. Verbakel, 2020, PloS one.

Pre-analytical error for three point of care venous blood testing platforms in acute ambulatory settings: A mixed methods service evaluation

M. Glogowska, T. Fanshawe, I. Smith, 2020, PloS one.

High activity of meropenem against Gram-negative bacteria from a paediatric Intensive Care Unit, 2001-2005.

P. Turner, D. Dzierżanowska, J. Patzer, 2007, International journal of antimicrobial agents.

Susceptibility patterns of Gram-negative bacteria from a Polish intensive care unit, 1997-2000.

P. Turner, D. Dzierżanowska, J. Patzer, 2002, International journal of antimicrobial agents.

Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997-2000).

P. Turner, C. Mendes, 2001, Diagnostic microbiology and infectious disease.

The Impact of Point-of-Care Blood C-Reactive Protein Testing on Prescribing Antibiotics in Out-of-Hours Primary Care: A Mixed Methods Evaluation

M. Glogowska, T. Fanshawe, L. Mwandigha, 2022, Antibiotics.

Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002).

P. Turner, 2005, Diagnostic microbiology and infectious disease.

The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000.

P. Turner, J. Greenhalgh, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.

P. Turner, 2006, Diagnostic microbiology and infectious disease.

AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro.

P. Turner, J. Clarke, C. Sefton, 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: A self-controlled case-series analysis.

E. Miller, J. Stowe, N. Andrews, 2020, Vaccine.

An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.

Ronald N. Jones, R. Masterton, P. Turner, 2005, Diagnostic microbiology and infectious disease.

In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I

P. Turner, J. R. Edwards, C. Wannop, 1989, Antimicrobial Agents and Chemotherapy.

Laboratory data which differentiate meropenem and imipenem.

P. Turner, Edwards, J. R. Edwards, 1995, Scandinavian journal of infectious diseases. Supplementum.

Emerging Antimicrobial Resistances Among Proteus mirabilis in Europe: Report from the MYSTIC Program (1997-2001)

A. Mutnick, P. Turner, R. Jones, 2002, Journal of chemotherapy.

Emerging resistance among Proteus mirabilis isolates in Europe : report from the MYSTIC program ( 1997-2001 )

A. Mutnick, P. Turner, R. Jones, 2002 .

Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003.

A. Hsiung, P. Turner, C. Mendes, 2005, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Antimicrobial susceptibility in intensive care units: MYSTIC Program Brazil 2002.

P. Turner, C. Mendes, C. Kiffer, 2005, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.

P. Turner, 2008, Diagnostic microbiology and infectious disease.

Extended-spectrum beta-lactamases.

P. Turner, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A compilation of studies assessing the in vitro activity of meropenem and comparators in 84 laboratories throughout Europe.

P. Turner, J. R. Edwards, 1997, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Trends in antimicrobial susceptibility in UK centres: the MYSTIC Programme (1997-2002).

R. Masterton, P. Turner, 2006, International journal of antimicrobial agents.

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview.

P. Turner, 2000, The Journal of antimicrobial chemotherapy.

MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.

P. Turner, 2009, Diagnostic microbiology and infectious disease.

Is stratification testing for treatment of chronic obstructive pulmonary disease exacerbations cost-effective in primary care? an early cost-utility analysis

N. Roberts, C. Butler, A. Van den Bruel, 2019, International Journal of Technology Assessment in Health Care.

S0266462318003707jra 116..125

N. Roberts, C. Butler, A. Van den Bruel, 2019 .

Frequencies and patterns of laboratory test requests from general practice: a service evaluation to inform point-of-care testing

Thomas R Fanshawe, Brian Shine, José M Ordóñez-Mena, 2018, Journal of Clinical Pathology.

Defining the role of host biomarkers in the diagnosis and prognosis of childhood pneumonia: a prospective cohort study

Y. Lubell, D. Limmathurotsakul, C. Koshiaris, 2022, medRxiv.

Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007).

P. Turner, D. Dzierżanowska, J. Patzer, 2008, The Journal of antimicrobial chemotherapy.

The MYSTIC (meropenem yearly susceptibility test information collection) programme.

P. Turner, J. R. Edwards, J. McKellar, 1999, International journal of antimicrobial agents.

Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs

Ronald N. Jones, S. Levy, T. O'Brien, 2005, Emerging infectious diseases.

Point-of-care testing in UK primary care: a survey to establish clinical needs

Matthew J. Thompson, C. Heneghan, A. Plüddemann, 2016, Family practice.

The comparative interrupted time series design for assessment of diagnostic impact: methodological considerations and an example using point-of-care C-reactive protein testing

T. Fanshawe, G. Hayward, P. Turner, 2022, Diagnostic and Prognostic Research.

Impact of point-of-care panel tests in ambulatory care: a systematic review and meta-analysis

A. Van den Bruel, J. Verbakel, P. S. Tan, 2020, BMJ Open.

Common evidence gaps in point-of-care diagnostic test evaluation: a review of horizon scan reports

Matthew J. Thompson, A. Plüddemann, C. Price, 2017, BMJ Open.

A Diagnostic Accuracy Study to Evaluate Standard Rapid Diagnostic Test (RDT) Alone to Safely Rule Out Imported Malaria in Children Presenting to UK Emergency Departments

T. Fanshawe, M. Lyttle, G. Hayward, 2023, Journal of the Pediatric Infectious Diseases Society.

Point-of-care Helicobacter pylori testing: primary care technology update.

C. Heneghan, A. Plüddemann, C. Price, 2017, The British journal of general practice : the journal of the Royal College of General Practitioners.

A compilation of meropenem tissue distribution data.

M. Hutchison, H. Nadler, P. Turner, 1995, The Journal of antimicrobial chemotherapy.

Evaluation of the diagnostic accuracy of two point-of-care tests for COVID-19 when used in symptomatic patients in community settings in the UK primary care COVID diagnostic accuracy platform trial (RAPTOR-C19)

R. Perera, B. Nicholson, T. Fanshawe, 2023, PloS one.

Primary care and point-of-care testing during a pandemic: Clinician's perspectives on integrating rapid testing for COVID-19 into the primary care pathway

B. Nicholson, G. Hayward, Yaling Yang, 2021, medRxiv.

Is stratification testing for treatment of chronic obstructive pulmonary disease exacerbations cost-effective in primary care? an early cost-utility analysis

N. Roberts, C. Butler, H. Dakin, 2019 .